Latham & Watkins Advises Halozyme on US$1.3 Billion Convertible Senior Notes Offerings

Latham & Watkins LLP represented the initial purchasers in the offering by Halozyme Therapeutics, Inc. Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the pricing of US$650 million aggregate principal amount of 0% convertible senior notes due 2031 and US$650 million aggregate principal amount of 0.875% convertible senior notes due 2032. The company also granted the initial purchasers a 13‑day option to purchase up to an additional US$100 million aggregate principal amount of the 2031 Notes and up to an additional US$100 million aggregate principal amount of the 2032 Notes. The convertible notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The company expects to close the offering on November 12, 2025, subject to the satisfaction of customary closing conditions. Latham & Watkins LLP represented the initial purchasers with a team composed by: Capital Markets partners Greg Rodgers and Andrew Blumenthal, with associates Ian Lachow and Steve Hess; Corporate partners Cheston Larson and Michael Sullivan, with associates Sterling Swift and Samantha Wang; Derivatives partner Reza Mojitabee‑Zamani, with associates Sloan Ungerman and Daniel Weiss; Tax partner Bora Bozkurt, with associate Jack Santoro; FDA regulatory counsel Chad Jennings; Healthcare regulatory partner Betty Pang; and Intellectual Property counsel Darryl Steensma, with associate Kristina Funahashi.

Latham & Watkins Advises Halozyme on US$1.3 Billion Convertible Senior Notes Offerings

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads